File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleFactors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
 
AuthorsO'Suilleabhain, CB1
Poon, RTP1
Yong, JL1
Ooi, GC1
Tso, WK1
Fan, ST1
 
Issue Date2003
 
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
 
CitationBritish Journal Of Surgery, 2003, v. 90 n. 3, p. 325-331 [How to Cite?]
DOI: http://dx.doi.org/10.1002/bjs.4045
 
AbstractBackground: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear. Methods: Pretreatment variables were analysed for factors predictive of actual 5-year survival from a prospective database of patients with inoperable HCC treated by TACE between 1989 and 1996. Results: Complete 5-year follow-up (median 91 months) was obtained for 320 patients who underwent a median of 4 (range 1-41) TACEs. Median tumour size was 9 (range 1-28) cm. There were 25 5-year survivors (8 per cent), including eight with tumours larger than 10 cm in diameter and three with portal vein branch involvement. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count below 150 × 109 per litre (P = 0.011), albumin concentration greater than 35 g/l (P = 0.04), α-fetoprotein level below 1000 ng/ml (P = 0.007), unilobar tumour (P = 0.027), fewer than three tumours (P = 0.015), absence of venous invasion (P = 0.011), and tumour diameter less than 8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin concentration greater than 35 g/l (P = 0.011), unilobar tumour (P = 0.012) and α-fetoprotein level below 1000 ng/ml (P = 0.014) were independent prognostic factors on multivariate analysis. Conclusion: Five-year survival is possible with TACE for inoperable HCC, even in some patients with advanced tumours. Unilobar tumours, α-fetoprotein level below 1000 ng/ml and albumin concentration greater than 35 g/l were factors predictive of 5-year survival.
 
ISSN0007-1323
2012 Impact Factor: 4.839
2012 SCImago Journal Rankings: 1.922
 
DOIhttp://dx.doi.org/10.1002/bjs.4045
 
ISI Accession Number IDWOS:000182437600010
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorO'Suilleabhain, CB
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorYong, JL
 
dc.contributor.authorOoi, GC
 
dc.contributor.authorTso, WK
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2010-09-06T08:39:20Z
 
dc.date.available2010-09-06T08:39:20Z
 
dc.date.issued2003
 
dc.description.abstractBackground: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear. Methods: Pretreatment variables were analysed for factors predictive of actual 5-year survival from a prospective database of patients with inoperable HCC treated by TACE between 1989 and 1996. Results: Complete 5-year follow-up (median 91 months) was obtained for 320 patients who underwent a median of 4 (range 1-41) TACEs. Median tumour size was 9 (range 1-28) cm. There were 25 5-year survivors (8 per cent), including eight with tumours larger than 10 cm in diameter and three with portal vein branch involvement. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count below 150 × 109 per litre (P = 0.011), albumin concentration greater than 35 g/l (P = 0.04), α-fetoprotein level below 1000 ng/ml (P = 0.007), unilobar tumour (P = 0.027), fewer than three tumours (P = 0.015), absence of venous invasion (P = 0.011), and tumour diameter less than 8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin concentration greater than 35 g/l (P = 0.011), unilobar tumour (P = 0.012) and α-fetoprotein level below 1000 ng/ml (P = 0.014) were independent prognostic factors on multivariate analysis. Conclusion: Five-year survival is possible with TACE for inoperable HCC, even in some patients with advanced tumours. Unilobar tumours, α-fetoprotein level below 1000 ng/ml and albumin concentration greater than 35 g/l were factors predictive of 5-year survival.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationBritish Journal Of Surgery, 2003, v. 90 n. 3, p. 325-331 [How to Cite?]
DOI: http://dx.doi.org/10.1002/bjs.4045
 
dc.identifier.doihttp://dx.doi.org/10.1002/bjs.4045
 
dc.identifier.epage331
 
dc.identifier.hkuros77825
 
dc.identifier.isiWOS:000182437600010
 
dc.identifier.issn0007-1323
2012 Impact Factor: 4.839
2012 SCImago Journal Rankings: 1.922
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmid12594668
 
dc.identifier.scopuseid_2-s2.0-0037339179
 
dc.identifier.spage325
 
dc.identifier.urihttp://hdl.handle.net/10722/83296
 
dc.identifier.volume90
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBritish Journal of Surgery
 
dc.relation.referencesReferences in Scopus
 
dc.rightsBritish Journal of Surgery. Copyright © John Wiley & Sons Ltd.
 
dc.titleFactors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>O&apos;Suilleabhain, CB</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Yong, JL</contributor.author>
<contributor.author>Ooi, GC</contributor.author>
<contributor.author>Tso, WK</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2010-09-06T08:39:20Z</date.accessioned>
<date.available>2010-09-06T08:39:20Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>British Journal Of Surgery, 2003, v. 90 n. 3, p. 325-331</identifier.citation>
<identifier.issn>0007-1323</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/83296</identifier.uri>
<description.abstract>Background: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear. Methods: Pretreatment variables were analysed for factors predictive of actual 5-year survival from a prospective database of patients with inoperable HCC treated by TACE between 1989 and 1996. Results: Complete 5-year follow-up (median 91 months) was obtained for 320 patients who underwent a median of 4 (range 1-41) TACEs. Median tumour size was 9 (range 1-28) cm. There were 25 5-year survivors (8 per cent), including eight with tumours larger than 10 cm in diameter and three with portal vein branch involvement. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count below 150 &#215; 109 per litre (P = 0.011), albumin concentration greater than 35 g/l (P = 0.04), &#945;-fetoprotein level below 1000 ng/ml (P = 0.007), unilobar tumour (P = 0.027), fewer than three tumours (P = 0.015), absence of venous invasion (P = 0.011), and tumour diameter less than 8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin concentration greater than 35 g/l (P = 0.011), unilobar tumour (P = 0.012) and &#945;-fetoprotein level below 1000 ng/ml (P = 0.014) were independent prognostic factors on multivariate analysis. Conclusion: Five-year survival is possible with TACE for inoperable HCC, even in some patients with advanced tumours. Unilobar tumours, &#945;-fetoprotein level below 1000 ng/ml and albumin concentration greater than 35 g/l were factors predictive of 5-year survival.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons Ltd. The Journal&apos;s web site is located at http://www.bjs.co.uk</publisher>
<relation.ispartof>British Journal of Surgery</relation.ispartof>
<rights>British Journal of Surgery. Copyright &#169; John Wiley &amp; Sons Ltd.</rights>
<title>Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0007-1323&amp;volume=90&amp;spage=325&amp;epage=331&amp;date=2003&amp;atitle=Factors+predictive+of+5-year+survival+after+transarterial+chemoembolization+for+inoperable+hepatocellular+carcinoma</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/bjs.4045</identifier.doi>
<identifier.pmid>12594668</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0037339179</identifier.scopus>
<identifier.hkuros>77825</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037339179&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>90</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>325</identifier.spage>
<identifier.epage>331</identifier.epage>
<identifier.isi>WOS:000182437600010</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong